Sign in

You're signed outSign in or to get full access.

Deborah Taylor Tate

Director at HEALTHSTREAM
Board

About Deborah Taylor Tate

Deborah Taylor Tate (age 67) has served as an independent director of HealthStream, Inc. since 2010 and is standing for re-election in 2025 to serve until the 2028 annual meeting . She is a licensed attorney; currently self-employed as a strategic consultant and attorney since 2022; and holds both undergraduate and J.D. degrees from the University of Tennessee, having also attended Vanderbilt Law School . Her background includes senior regulatory, legal, and policy roles at state and federal levels, including service as an FCC Commissioner (2005–2009) and leadership within Tennessee regulatory bodies .

Past Roles

OrganizationRoleTenureCommittees/Impact
Administrative Office of the Courts (Tennessee Supreme Court/State of Tennessee)Director2015–2022 Member, American Judges Association; Conference of State Court Administrators national board until Feb 2022
Federal Communications CommissionCommissioner (only female at the time); Chair of two Federal Joint Boards2005–2009 Represented FCC at ITU; named first ITU Envoy for children’s internet policy; Laureate for Childhood Online Protection
Tennessee Consolidated Retirement System BoardBoard member; elected to Audit CommitteeUntil Feb 2022 Oversight of ~$60B pension fund; audit oversight
Tennessee Regulatory AuthorityChairman and DirectorAt time of presidential appointment (noted) State regulatory body for telecom and utilities
Health Facilities Commission (Tennessee)Executive DirectorNot specified Oversight of healthcare facility and services regulation
National Judicial Opioid Task ForceNational Co-chair2017–2021 Developed training/resources re: opioid epidemic to thousands of judges
American Judges Association; Conference of State Court AdministratorsMember; National board (CSCA)Through Feb 2022 Judicial leadership and governance
Office(s) of Sen. Lamar Alexander; Gov. Don SundquistLegal counsel/senior staffNot specified Senior policy and legal advisory roles

External Roles

OrganizationRoleTenureNotes
Leadership Nashville Alumni AssociationPresident, Executive BoardCurrent Civic leadership
Multicultural Media, Telecommunications and Internet Council (MMTC)Vice-ChairmanSince 2021 National telecom/media policy organization
Community Foundation of Middle TennesseeCo-Chair and TrusteeCurrent Philanthropy; co-founded programs for mothers/children affected by addiction; financial literacy program for girls
Centerstone AmericaCo-Chair, Council of National Policy AdvisorsPresent Leading informatics/analytics/clinical research provider for behavioral healthcare

Board Governance

  • Independence: The Board determined Tate is independent under Nasdaq listing standards; all standing committees are composed solely of independent directors .
  • Committees: Member of the Nominating and Corporate Governance Committee (with Thompson Dent, Chair, and Alex Jahangir, M.D.) . Not listed as a member of the Audit or Compensation committees .
  • Attendance: In 2024, the Board held seven meetings; Audit Committee seven; Compensation Committee five; Nominating & Corporate Governance six; each director attended 100% of Board and applicable committee meetings, and attended the virtual annual meeting .
  • Lead Independent Director and Executive Sessions: Independent directors meet in executive session at least twice annually; the Lead Independent Director presides (Lead Independent Director role held by Thompson S. Dent as noted in 2024) .
  • Risk oversight: Audit Committee oversees risk management, including privacy, data, cybersecurity, AI, and information security; Nominating & Corporate Governance oversees ESG and, jointly with the Audit Committee, the Incident Response Policy reviewed annually .
  • Overboarding guardrail: Governance principles limit directors to no more than two other public company boards without Board approval, consistent with conflict policies .

Fixed Compensation

YearCash Retainer ($)Additional Committee/Chair Fees ($)Paid in Stock ($)Total Cash/Stock Fees ($)
202430,000 N/A for Tate; Audit member fee 32,500; Audit Chair & Lead Independent/Nominating Chair +10,000; Comp Chair +2,750 (program terms) 30,000

Notes:

  • Non-employee directors may elect to receive shares in lieu of cash compensation under the 2022 Plan (election due by end of prior year) .
  • The cash program transitioned in 2024 from flat fees in 2023 to annual retainers, with increased chair premiums .

Performance Compensation

Grant YearEquity TypeShares GrantedGrant Date Fair Value ($)VestingPerformance Conditions
2024RSUs3,018 81,999 Vest annually in three equal increments on the first, second, and third anniversaries, subject to continued service as director None; time-based RSUs (no performance metrics for director equity)

Outstanding RSUs at FY-end 2024 for Tate: 6,419 .

Other Directorships & Interlocks

  • Current public company directorships: None disclosed beyond HealthStream .
  • Committee roles at other companies: Not disclosed .
  • Related-party transactions: Proxy disclosed certain vendor agreements involving directors Dent and McLaren; no related-party arrangements involving Tate were disclosed, and those noted were arms-length per policy .

Expertise & Qualifications

  • Licensed attorney; extensive regulatory and policy experience (FCC commissioner; Tennessee regulatory leadership) .
  • Healthcare oversight exposure (Health Facilities Commission; Centerstone; judicial opioid task force) .
  • Pension/audit oversight experience via TCRS Board Audit Committee .
  • Recognitions include ITU Envoy designation and Laureate for Childhood Online Protection; multiple public service awards; honored by Tennessee General Assembly in 2023 .

Equity Ownership

HolderShares Beneficially OwnedPercent of OutstandingBasis DateNotes
Deborah Taylor Tate22,575 Less than 1% March 31, 2025 RSUs vesting within 60 days count toward individual ownership for percent calc; total shares outstanding 30,525,266

Alignment policies:

  • Anti-hedging: Directors and specified executives are prohibited from hedging or monetization transactions in Company securities under the Insider Trading Policy .

Insider trades (Section 16(a) compliance):

Transaction DateForm 4 Filing DateTypeSharesNote
Nov 20, 2024Nov 25, 2024Gift900 Reported late (Company notes delinquent filing)

Governance Assessment

  • Board effectiveness and engagement: 100% attendance across Board and committees in 2024 indicates strong engagement; standing committees are fully independent .
  • Committee contributions: Tate serves on Nominating & Corporate Governance, which oversees ESG, board skills/evaluations, succession planning, and incident response policy — roles aligned to governance quality and investor confidence .
  • Independence and conflicts: Board affirms Tate’s independence; no related-party dealings involving Tate disclosed; vendor agreements noted in proxy involve other directors and were arms-length under policy .
  • Incentive alignment: Director equity is time-based RSUs with three-year vesting; while common for directors, absence of performance conditions means equity is retention-focused rather than performance-linked .
  • Policies: Strong anti-hedging policy supports alignment; clawback policy maintained for executive officers under SEC/Nasdaq rules (Compensation Recoupment Policy) .
  • Risk indicators: Minor administrative issue — late Form 4 for a gift transaction (900 shares) filed five days after the gift; no investigations or related-party exposures disclosed for Tate in the proxy .
  • Overboarding risk control: Governance limit on other public boards reduces risk of overboarding; no other public company boards disclosed for Tate .

Board Governance (Additional Detail)

CommitteeRoleMembership Period
Nominating & Corporate GovernanceMemberCurrent; 2024 membership: Dent (Chair), Jahangir, Tate
AuditNot a member2024 members: Rappuhn (Chair), Stead, Rebrovick; 2025 addition of Beard
CompensationNot a member2024 members: Gordon (Chair), Rebrovick, McLaren

Fixed Compensation (Detail Table for 2024 Director Pay)

ComponentAmount ($)
Fees Earned – Paid in Cash30,000
Fees Earned – Paid in Stock
Stock Awards (RSUs, grant-date fair value)81,999
Total111,999

Performance Compensation (Metric Table)

MetricStructureTerms
RSU Grant Size (2024)3,018 RSUs Granted under 2022 Plan; directors must remain in service to vest
Grant-Date Fair Value$81,999 FASB ASC Topic 718; see 10-K Note 10 for assumptions
Vesting ScheduleTime-based1/3 annually on 1st, 2nd, 3rd anniversaries of grant
Performance ConditionsNoneNo revenue/EBITDA/TSR metrics for director awards

Other Directorships & Interlocks

Company/OrganizationTypeRolePotential Interlock/Conflict
None disclosed (public companies)PublicNo public company interlocks disclosed
MMTCNon-profit/PolicyVice-ChairmanNo HealthStream related-party payments disclosed
Community Foundation of Middle TennesseeNon-profitCo-Chair/TrusteeNo HealthStream related-party payments disclosed
Centerstone AmericaNon-profit/HealthcareCo-Chair, Council of National Policy AdvisorsNo HealthStream related-party payments disclosed

Equity Ownership

SecurityVestedUnvestedNotes
Common Shares22,575 <1% of outstanding (30,525,266 shares basis)
RSUs Outstanding (FY-end 2024)6,419 Time-based vesting

Governance Signals and RED FLAGS

  • Positive signals: Independence confirmed; 100% attendance; ESG/succession oversight via Nominating & Corporate Governance; anti-hedging policy; structured director compensation with equity component .
  • Red flags: Director RSUs are purely time-based (no performance link); late Form 4 gift filing noted (administrative) .
  • Conflicts: No related-party transactions disclosed for Tate; other directors’ ordinary-course vendor agreements were arms-length and did not involve Tate .